Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE)

NCT02065791 PHASE3 COMPLETED Results posted

The goal of this study is to assess whether canagliflozin has a renal and vascular protective effect in reducing the progression of renal impairment relative to placebo in participants with type 2 diabetes mellitus (T2DM), Stage 2 or 3 chronic kidney disease (CKD) and macroalbuminuria, who are receiving standard of care including a maximum tolerated labeled daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB).

Details

Lead sponsor	Janssen Research & Development, LLC
Phase	PHASE3
Status	COMPLETED
Enrolment	4401
Start date	Mon Feb 17 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Oct 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Diabetes Mellitus, Type 2
• Diabetic Nephropathy

Interventions

• Canagliflozin
• Placebo

Countries

Colombia, Japan, Malaysia, Taiwan, Poland, South Korea, Philippines, Guatemala, New Zealand, Russia, Mexico, Lithuania, Bulgaria, Czechia, United States, France, South Africa, Slovakia, Serbia, Chile, Hungary, Argentina, Canada, Puerto Rico, Romania, Brazil, Spain, Ukraine, United Kingdom, Germany